CASC3 and plasma cell myeloma: This observation is also in agreement with our previous findings that co-inhibition of β2 sites overcomes Btz resistance in primary cells from myeloma patients26, and that combined β2 and β5 inhibition produces a stronger anti-neoplastic effect than combined β1 and β5 inhibition25.